Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 17 01 2020
accepted: 14 07 2020
pubmed: 22 9 2020
medline: 17 2 2021
entrez: 21 9 2020
Statut: ppublish

Résumé

BACKGROUNDCytotoxic T lymphocyte antigen 4 (CTLA4) is essential for immune homeostasis. Genetic mutations causing haploinsufficiency (CTLA4h) lead to a phenotypically heterogenous, immune-mediated disease that can include neuroinflammation. The neurological manifestations of CTLA4h are poorly characterized.METHODSWe performed an observational natural history study of 50 patients with CTLA4h who were followed at the NIH. We analyzed clinical, radiological, immunological, and histopathological data.RESULTSEvidence for neuroinflammation was observed in 32% (n = 16 of 50) of patients in this cohort by magnetic resonance imaging (MRI) and/or by cerebrospinal fluid analysis. Clinical symptoms were commonly absent or mild in severity, with headaches as the leading complaint (n = 13 of 16). The most striking findings were relapsing, large, contrast-enhancing focal lesions in the brain and spinal cord observed on MRI. We detected inflammation in the cerebrospinal fluid and leptomeninges before the parenchyma. Brain biopsies of inflammatory lesions from 10 patients showed perivascular and intraparenchymal mixed cellular infiltrates with little accompanying demyelination or neuronal injury.CONCLUSIONSNeuroinflammation due to CTLA4h is mediated primarily by an infiltrative process with a distinct and striking dissociation between clinical symptoms and radiological findings in the majority of patients.FUNDINGNIAID, NIH, Division of Intramural Research, NINDS, NIH, Division of Intramural Research, and the National Multiple Sclerosis Society-American Brain Foundation.TRIAL REGISTRATIONClinicalTrials.gov NCT00001355.

Identifiants

pubmed: 32955488
pii: 135947
doi: 10.1172/JCI135947
pmc: PMC7524497
doi:
pii:

Substances chimiques

CTLA-4 Antigen 0
CTLA4 protein, human 0

Banques de données

ClinicalTrials.gov
['NCT00001355']

Types de publication

Journal Article Observational Study Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5551-5561

Références

Neuro Oncol. 2014 Apr;16(4):589-93
pubmed: 24482447
Ann Rheum Dis. 2008 Aug;67(8):1096-103
pubmed: 18055472
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Med. 2014 Dec;20(12):1410-1416
pubmed: 25329329
Immunity. 1997 Dec;7(6):885-95
pubmed: 9430233
Pract Neurol. 2013 Aug;13(4):278-80
pubmed: 23487828
J Immunother. 2015 Feb-Mar;38(2):77-9
pubmed: 25658617
JAMA Neurol. 2016 Aug 1;73(8):928-33
pubmed: 27271951
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
Science. 2014 Sep 26;345(6204):1623-1627
pubmed: 25213377
PLoS Pathog. 2018 Apr 30;14(4):e1007042
pubmed: 29709026
J Exp Med. 1991 Sep 1;174(3):561-9
pubmed: 1714933
Oncologist. 2013 Jun;18(6):733-43
pubmed: 23774827
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
J Oncol Pharm Pract. 2016 Jun;22(3):537-42
pubmed: 25712627
J Exp Med. 1992 Dec 1;176(6):1595-604
pubmed: 1334116
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
Ann Oncol. 2011 Apr;22(4):991-993
pubmed: 21357649
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Neurology. 2016 Apr 19;86(16):1553-6
pubmed: 26984943
Neurology. 2017 Apr 11;88(15):1439-1444
pubmed: 28283598
Ann Neurol. 2016 Aug;80(2):294-300
pubmed: 27351142

Auteurs

Matthew K Schindler (MK)

Neuroimmunology Clinic and.
Translational Neuroradiology Section, National Institutes of Neurological Diseases and Stroke (NINDS).

Stefania Pittaluga (S)

Laboratory of Pathology, National Cancer Institute (NCI).

Yoshimi Enose-Akahata (Y)

Viral Immunology Section, NINDS, and.

Helen C Su (HC)

Human Immunological Diseases Section and.

V Koneti Rao (VK)

Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease (NIAID), NIH, Bethesda, Maryland, USA.

Amy Rump (A)

Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease (NIAID), NIH, Bethesda, Maryland, USA.

Steven Jacobson (S)

Viral Immunology Section, NINDS, and.

Irene Cortese (I)

Neuroimmunology Clinic and.

Daniel S Reich (DS)

Neuroimmunology Clinic and.
Translational Neuroradiology Section, National Institutes of Neurological Diseases and Stroke (NINDS).

Gulbu Uzel (G)

Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease (NIAID), NIH, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH